EAST ST. LOUIS, Ill. - Eli Lilly and Co. on March 17 urged the Pradaxa multidistrict litigation court not to sanction it for the alleged "contumacious" testimony by a former company executive, saying the testimony the plaintiffs are trying to elicit is irrelevant or the motion is premature (In Re: Actos $(Pioglitazone$) Products Liability Litigation, MDL Docket No. 2299, No. 6:11-md-2299, Terrence Allen, et al. v. Takeda Pharmaceuticals International, Inc., No. 6:12-64, S.D. Ill.).